♥ OVERVIEW
Cross-sectional observational study designed to identify and describe the care gap in guideline-oriented low density lipoprotein cholesterol (LDL-C) management in Canadian patients at high cardiovascular risk.
♥ DETAILED DESCRIPTION
This is a cross-sectional observational study designed to provide real-life data on the current management of dyslipidemia in high cardiovascular risk patients in routine clinical practice. Canadian guidelines recommend a target for LDL-C of ≤2.0 mmol/L (or ≥50% decrease) after treatment initiation in high-risk patients. The recommended first line treatment is statin therapy. Available data clearly indicates that up to 50% of high risk patients do not achieve this important target because of statin inadequacy or intolerance leading to non-adherence. Therefore this program aims to provide further insights into the challenges Canadian physicians face in helping their high risk patients achieve guideline-recommended LDL-C.
♥ INCLUSION CRITERIA
- ADULTS >18 YEARS OLD
- HIGH RISK FOR CARDIOVASCULAR MORBIDITY OR MORTALITY (AT LEAST ONE OF THE FF)
A. CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (CVD)
- Acute Coronary Syndrome (ACS: MI, Unstable Angina)
- Coronary Revascularization (PCI, CABG)
- Stable Angina
B. FAMILIAL HYPERCHOLESTEROLEMIA
DEFINED AS LDL-C >5 mmol/L (Current or prior to treatment with lipid lowering medications) and at least one of the following:
- Typical physical findings (stigmata) such as tendon xanthomata, xanthelasma and arcus corneae
- Personal history of early cardiovascular disease (PCI, CABG)
- Family History of early cardiovascular disease or marked hyperlipidemia
- DNA- based evidence of FH or presence of functional mutation in an FH related gene.
3. RECEIVING CURRENT OPTIMAL (MAXIMAL OR MAXIMAL TOLERATED STATIN THERAPY FOR AT LEAST 3 MONTHS PRIOR TO PATIENT ENROLLMENT.
4. LDL-C ABOVE CURRENTLY RECOMMENDED TARGET BY THE CANADIAN CARDIOVASCULAR SOCIETY MEASURED WHILE ON MAXIMAL TOLERATED STATIN THERAPY (+ OTHER LIPID MODIFYING THERAPIES)
DESIRE ABILITY TO EXECUTE THE CONSENT TO PARTICIPATE
♥ EXCLUSION
- CURRENT TREATMENT WITH PCSK9 INHIBITOR
- PARTICIPATION IN AN INVESTIGATIONAL STUDY
- PRIOR PARTICIPATION IN THE GOAL PROGRAM
If you meet these criteria and is interested to participate in this research study or if you need more information regarding the study, please contact us at 403-235-4109 or e-mail us at hfnurse@arcnetwork.ca